Edition:
United States

BioLine RX Ltd (BLRX.TA)

BLRX.TA on Tel Aviv Stock Exchange

369.00ILa
19 Sep 2017
Change (% chg)

0.50 (+0.14%)
Prev Close
368.50
Open
368.50
Day's High
373.70
Day's Low
368.50
Volume
44,080
Avg. Vol
113,914
52-wk High
500.00
52-wk Low
286.60

Latest Key Developments (Source: Significant Developments)

Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization
Monday, 21 Aug 2017 07:00am EDT 

Aug 21 (Reuters) - Bioline Rx Ltd ::Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization.Bioline RX Ltd - ‍initiation of study expected by end of 2017​.Bioline RX Ltd- ‍trial, named genesis, is expected to commence by end of 2017, following receipt of regulatory approval​.  Full Article

Biolinerx Q2 ‍loss per share $0.05​
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Bioline Rx Ltd ::Biolinerx reports second quarter 2017 financial results.Qtrly ‍loss per share $0.05​.  Full Article

Biolinerx announces additional investment from BVF Partners L.P.
Wednesday, 26 Jul 2017 07:00am EDT 

July 26 (Reuters) - BiolineRx Ltd :BiolineRx announces additional investment from BVF partners L.P..BiolineRx Ltd - BVF partners L.P enters into a definitive agreement to make an additional, direct investment of $9.6 million in biolinerx.BiolineRX Ltd - bvf's new investment is priced at $1.13 per unit.BiolineRX Ltd - each unit consists of 1 ordinary share, 0.35 of a series A warrant, and 0.35 of a series B warrant.BiolineRX Ltd - BVF Partners L.P raises its economic interest in BiolineRX to 24.9 percent.  Full Article

BiolineRx reports regulatory submissions of 3 Phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors
Thursday, 1 Jun 2017 07:00am EDT 

June 1 (Reuters) - Bioline Rx Ltd ::BiolineRx reports regulatory submissions of three phase 1b trials for BL-8040 in combination with atezolizumab for solid tumors.Bioline Rx - trials for pancreatic, gastric and non-small cell cancer expected to commence during second half of 2017, after receipt of regulatory approval.  Full Article

BioLine Rx reports Q1 loss per share $0.06
Thursday, 25 May 2017 07:00am EDT 

May 25 (Reuters) - BioLine Rx Ltd :BioLine Rx reports first quarter 2017 financial results.BioLine Rx Ltd qtrly loss per share $0.06.  Full Article

Biolinerx announces regulatory submission for phase 1B trial of BL-8040
Monday, 22 May 2017 07:00am EDT 

May 22 (Reuters) - Bioline Rx Ltd :Biolinerx announces regulatory submission for phase 1B trial of BL-8040 in combination with atezolizumab in AML.Trial, named battle, is expected to commence in second half of 2017, following receipt of regulatory approval.  Full Article

BioLineRx to begin late-stage study testing stem cell treatment
Wednesday, 3 May 2017 07:00am EDT 

May 3 (Reuters) - Bioline Rx Ltd :Biolinerx to initiate phase 3 study with bl-8040 as novel stem cell mobilization treatment following successful meeting with fda.Bioline rx ltd- initiation of phase 3 registrational study expected in second half of the year for bl-8040.Bioline rx ltd- initiation of phase 3 registrational study expected in second half of this year.Bioline rx ltd- met with u.s. Fda and has gained clarity on development program and design of a phase 3 pivotal study for bl-8040.  Full Article

BVF Inc reports 18.3 pct passive stake in Bioline RX Ltd
Monday, 10 Apr 2017 05:26pm EDT 

Bioline RX Ltd :BVF Inc reports 18.3 percent passive stake in Bioline RX Ltd as on March 31, 2017.  Full Article

BioLine RX announces underwritten public offering of its american depositary shares
Thursday, 30 Mar 2017 04:01pm EDT 

BioLine Rx Ltd : BioLine RX announces underwritten public offering of its american depositary shares .BioLine RX Ltd - all of ADSs in offering are to be sold by BioLine RX.  Full Article

BiolineRX announces acquisition of Agalimmune Ltd
Thursday, 23 Mar 2017 07:00am EDT 

BiolineRX Ltd : Biolinerx announces acquisition of Agalimmune Ltd to accelerate expansion of immuno-oncology pipeline . BiolineRX Ltd - acquisition consideration consisted of a $6 million upfront payment .BiolineRX ltd - acquisition consideration consisted of $3 million in cash and remainder in biolineRX shares.  Full Article

BRIEF-Biolinerx announces regulatory submission of phase 3 registrational study for BL-8040 in stem cell mobilization

* Biolinerx announces regulatory submission of phase 3 registrational study for bl-8040 in stem cell mobilization